Citigroup Cuts Abbott Laboratories (NYSE:ABT) Price Target to $136.00

Abbott Laboratories (NYSE:ABT) had its price target decreased by Citigroup from $140.00 to $136.00 in a research note released on Wednesday morning,Benzinga reports. Citigroup currently has a buy rating on the healthcare product maker’s stock.

Other analysts have also issued research reports about the company. Oppenheimer decreased their price objective on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Daiwa Securities Group reduced their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Evercore decreased their price target on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Barclays lowered their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a report on Monday, February 2nd. Finally, Leerink Partners reduced their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $136.16.

Abbott Laboratories Stock Down 0.1%

Shares of ABT opened at $107.99 on Wednesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The company has a 50-day simple moving average of $114.58 and a 200-day simple moving average of $123.91. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $139.06. The firm has a market capitalization of $187.66 billion, a P/E ratio of 29.03, a P/E/G ratio of 1.72 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period last year, the business earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Insider Buying and Selling

In other news, VP John A. Jr. Mccoy sold 585 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the transaction, the vice president directly owned 24,628 shares in the company, valued at approximately $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The stock was bought at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the acquisition, the director owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders sold 3,055 shares of company stock valued at $353,097. Insiders own 0.46% of the company’s stock.

Hedge Funds Weigh In On Abbott Laboratories

Several large investors have recently made changes to their positions in the company. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories during the 4th quarter worth about $25,000. Cornerstone Financial Management LLC acquired a new position in Abbott Laboratories during the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new position in shares of Abbott Laboratories in the 4th quarter valued at about $26,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $26,000. Finally, Harbor Capital Advisors Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter worth approximately $27,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.